IN2014DN06169A - - Google Patents
Info
- Publication number
- IN2014DN06169A IN2014DN06169A IN6169DEN2014A IN2014DN06169A IN 2014DN06169 A IN2014DN06169 A IN 2014DN06169A IN 6169DEN2014 A IN6169DEN2014 A IN 6169DEN2014A IN 2014DN06169 A IN2014DN06169 A IN 2014DN06169A
- Authority
- IN
- India
- Prior art keywords
- salts
- compositions
- methods
- cyclic compounds
- certain fused
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2011/085148 WO2013097225A1 (en) | 2011-12-31 | 2011-12-31 | Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN06169A true IN2014DN06169A (de) | 2015-08-21 |
Family
ID=48696280
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN6169DEN2014 IN2014DN06169A (de) | 2011-12-31 | 2011-12-31 |
Country Status (29)
Country | Link |
---|---|
US (4) | US9260440B2 (de) |
EP (2) | EP2797921B1 (de) |
JP (1) | JP6034877B2 (de) |
KR (1) | KR101716012B1 (de) |
CN (2) | CN103703004B (de) |
AU (1) | AU2011384858B2 (de) |
BR (1) | BR112014012628B8 (de) |
CA (1) | CA2856309C (de) |
CY (1) | CY1119804T1 (de) |
DK (1) | DK2797921T3 (de) |
EA (1) | EA027533B1 (de) |
ES (1) | ES2645814T3 (de) |
HK (1) | HK1192233A1 (de) |
HR (1) | HRP20171883T1 (de) |
HU (1) | HUE035153T2 (de) |
IL (1) | IL233365A (de) |
IN (1) | IN2014DN06169A (de) |
LT (1) | LT2797921T (de) |
ME (1) | ME02855B (de) |
MX (1) | MX353578B (de) |
NO (1) | NO2797921T3 (de) |
NZ (1) | NZ624063A (de) |
PL (1) | PL2797921T3 (de) |
PT (1) | PT2797921T (de) |
RS (1) | RS56616B1 (de) |
SG (1) | SG11201401726VA (de) |
SI (1) | SI2797921T1 (de) |
WO (1) | WO2013097225A1 (de) |
ZA (1) | ZA201405560B (de) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2797921T3 (en) | 2011-12-31 | 2017-10-02 | Beigene Ltd | FUSED TETRA- OR PENTA-CYCLIC DIHYDRODIAZEPINOCARBAZOLONES AS PARB INHIBITORS |
KR102104144B1 (ko) | 2012-03-07 | 2020-04-23 | 디 인스티튜트 오브 캔서 리서치:로얄 캔서 하스피틀 | 3-아릴-5-치환-이소퀴놀린-1-온 화합물 및 그의 치료적 용도 |
DK3044221T3 (en) | 2013-09-11 | 2018-04-23 | Institute Of Cancer Res Royal Cancer Hospital The | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ON COMPOUNDS AND THERAPEUTIC APPLICATION THEREOF |
BR112018003634B1 (pt) * | 2015-08-25 | 2023-11-21 | Beigene Switzerland Gmbh | Forma cristalina de sesqui-hidrato de um inibidor parp, método de preparação da dita forma cristalina e composição farmacêutica compreendendo a dita forma |
RU2738646C2 (ru) * | 2016-04-01 | 2020-12-15 | РЕКЬЮРИУМ АйПи ХОЛДИНГС, ЛЛС | Модуляторы эстрогеновых рецепторов |
EP3519051B1 (de) * | 2016-09-27 | 2021-09-22 | Beigene, Ltd. | Behandlung von krebs durch kombination mit parp-inhibitoren |
CN115433187B (zh) * | 2017-02-28 | 2023-10-27 | 百济神州(苏州)生物科技有限公司 | 稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式组合物及其用途 |
CN106883232B (zh) * | 2017-03-31 | 2019-01-22 | 苏州康润医药有限公司 | 一种氮杂非那烯-3-酮的衍生物及其制备方法与应用 |
US20200155567A1 (en) * | 2017-07-17 | 2020-05-21 | Beigene, Ltd. | Treatment of cancers using a combination comprising parp inhibitors, temozolomide and/or radiation therapy |
US20210205323A1 (en) * | 2018-06-01 | 2021-07-08 | Beigene, Ltd. | Maintenance therapy of a parp inhibitor in treating gastric cancer |
CN111171031B (zh) * | 2019-05-10 | 2021-04-09 | 百济神州(苏州)生物科技有限公司 | 一种含parp抑制剂倍半水合物产物的制备方法 |
CN111171002B (zh) * | 2019-05-16 | 2021-04-06 | 百济神州(苏州)生物科技有限公司 | 一种parp抑制剂中间体的制备方法 |
AU2020282478A1 (en) * | 2019-05-31 | 2021-09-16 | Beigene, Ltd. | PARP inhibitor pellet preparation and preparation process therefor |
JP2022543832A (ja) | 2019-08-06 | 2022-10-14 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | 変異体を治療するためのエストロゲン受容体調節剤 |
WO2021046014A1 (en) | 2019-09-03 | 2021-03-11 | Teva Czech Industries S.R.O | Solid state forms of pamiparib and process for preparation thereof |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE445326B (sv) | 1983-04-05 | 1986-06-16 | Malmstroem Anders E H | Sett och anordning for forhindrande av veggturbulens |
US6799298B2 (en) | 1998-03-11 | 2004-09-28 | Overture Services, Inc. | Technique for locating an item of interest within a stored representation of data |
MXPA01007001A (es) | 1999-01-11 | 2002-07-30 | Agouron Pharma | Inhibidores triciclicos de poli (adp-ribosa) polimerasas. |
WO2002044183A2 (en) | 2000-12-01 | 2002-06-06 | Guilford Pharmaceuticals Inc. | Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors |
US6423705B1 (en) | 2001-01-25 | 2002-07-23 | Pfizer Inc. | Combination therapy |
US6906096B2 (en) | 2002-06-28 | 2005-06-14 | Irm Llc | 4,7-Disubstituted indoles and methods of making |
GEP20084367B (en) | 2003-01-09 | 2008-05-13 | Pfizer | Diazepinoindole derivatives as kinase inhibitors |
WO2004105700A2 (en) | 2003-05-28 | 2004-12-09 | Guildford Pharmaceuticals, Inc. | Compounds, methods and pharmaceutical compositions for inhibiting parp |
EP2007375A1 (de) | 2006-04-04 | 2008-12-31 | Pfizer Products Inc. | Kombinationstherapie von (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4-yl)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamid |
EP2004655A1 (de) | 2006-04-04 | 2008-12-24 | Pfizer Products Incorporated | Polymorphe formen von (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h)pyrazol-4-yl)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamid |
NZ585395A (en) | 2007-11-15 | 2012-03-30 | Angeletti P Ist Richerche Bio | Pyridazinone derivatives as parp inhibitors |
US8012976B2 (en) * | 2008-08-06 | 2011-09-06 | Biomarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) |
WO2011130661A1 (en) | 2010-04-16 | 2011-10-20 | Biomarin Pharmaceutical Inc. | Methods of using dihydropyridophthalazinone inhibitors of poly (adp-ribose)polymerase (parp) |
DK2797921T3 (en) | 2011-12-31 | 2017-10-02 | Beigene Ltd | FUSED TETRA- OR PENTA-CYCLIC DIHYDRODIAZEPINOCARBAZOLONES AS PARB INHIBITORS |
JP6623353B2 (ja) | 2013-09-13 | 2019-12-25 | ベイジーン スウィッツァーランド ゲーエムベーハー | 抗pd−1抗体並びにその治療及び診断のための使用 |
TWI687438B (zh) | 2014-07-03 | 2020-03-11 | 英屬開曼群島商百濟神州生物科技有限公司 | 抗pd-l1抗體及其作為治療及診斷之用途 |
US9637488B2 (en) | 2015-01-29 | 2017-05-02 | Fuqiang Ruan | Heterocyclic compounds as inhibitors of class I PI3KS |
BR112018003634B1 (pt) | 2015-08-25 | 2023-11-21 | Beigene Switzerland Gmbh | Forma cristalina de sesqui-hidrato de um inibidor parp, método de preparação da dita forma cristalina e composição farmacêutica compreendendo a dita forma |
EP3519051B1 (de) | 2016-09-27 | 2021-09-22 | Beigene, Ltd. | Behandlung von krebs durch kombination mit parp-inhibitoren |
CN115433187B (zh) | 2017-02-28 | 2023-10-27 | 百济神州(苏州)生物科技有限公司 | 稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式组合物及其用途 |
US20200155567A1 (en) | 2017-07-17 | 2020-05-21 | Beigene, Ltd. | Treatment of cancers using a combination comprising parp inhibitors, temozolomide and/or radiation therapy |
-
2011
- 2011-12-31 DK DK11878508.8T patent/DK2797921T3/en active
- 2011-12-31 EP EP11878508.8A patent/EP2797921B1/de active Active
- 2011-12-31 CA CA2856309A patent/CA2856309C/en active Active
- 2011-12-31 PT PT118785088T patent/PT2797921T/pt unknown
- 2011-12-31 RS RS20171228A patent/RS56616B1/sr unknown
- 2011-12-31 EA EA201491303A patent/EA027533B1/ru not_active IP Right Cessation
- 2011-12-31 ME MEP-2017-278A patent/ME02855B/de unknown
- 2011-12-31 NZ NZ624063A patent/NZ624063A/en unknown
- 2011-12-31 CN CN201180072418.8A patent/CN103703004B/zh active Active
- 2011-12-31 BR BR112014012628A patent/BR112014012628B8/pt active IP Right Grant
- 2011-12-31 EP EP17183473.2A patent/EP3315500B1/de active Active
- 2011-12-31 PL PL11878508T patent/PL2797921T3/pl unknown
- 2011-12-31 IN IN6169DEN2014 patent/IN2014DN06169A/en unknown
- 2011-12-31 SI SI201131351T patent/SI2797921T1/en unknown
- 2011-12-31 CN CN201610603192.4A patent/CN106220635B/zh active Active
- 2011-12-31 LT LTEP11878508.8T patent/LT2797921T/lt unknown
- 2011-12-31 WO PCT/CN2011/085148 patent/WO2013097225A1/en active Application Filing
- 2011-12-31 ES ES11878508.8T patent/ES2645814T3/es active Active
- 2011-12-31 JP JP2014549295A patent/JP6034877B2/ja active Active
- 2011-12-31 MX MX2014007840A patent/MX353578B/es active IP Right Grant
- 2011-12-31 NO NO11878508A patent/NO2797921T3/no unknown
- 2011-12-31 KR KR1020147018104A patent/KR101716012B1/ko active IP Right Grant
- 2011-12-31 HU HUE11878508A patent/HUE035153T2/en unknown
- 2011-12-31 US US14/369,374 patent/US9260440B2/en active Active
- 2011-12-31 AU AU2011384858A patent/AU2011384858B2/en active Active
- 2011-12-31 SG SG11201401726VA patent/SG11201401726VA/en unknown
-
2014
- 2014-06-12 HK HK14105542.6A patent/HK1192233A1/zh unknown
- 2014-06-25 IL IL233365A patent/IL233365A/en active IP Right Grant
- 2014-07-28 ZA ZA2014/05560A patent/ZA201405560B/en unknown
-
2016
- 2016-01-05 US US14/988,484 patent/US9617273B2/en active Active
-
2017
- 2017-04-05 US US15/479,958 patent/US10112952B2/en active Active
- 2017-11-16 CY CY20171101198T patent/CY1119804T1/el unknown
- 2017-12-04 HR HRP20171883TT patent/HRP20171883T1/hr unknown
-
2018
- 2018-09-19 US US16/135,512 patent/US10501467B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014DN06169A (de) | ||
IN2014DN06166A (de) | ||
CO7111289A2 (es) | Compuestos inhibidores de metaloenzimas | |
IN2015DN00127A (de) | ||
UY33958A (es) | Inhibidores de la glucosilceramida sintasa | |
IN2014CN02283A (de) | ||
UY33930A (es) | Inhibidores novedosos de quinasas | |
CR20140106A (es) | Compuestos y composiciones como inhibidores de la quinasa c-kit | |
UY34836A (es) | Nuevo organismos | |
UY34602A (es) | ?Derivados de bencimidazolil- e imidazopiridinil-metilamina? | |
IN2012DE02913A (de) | ||
UY34365A (es) | Compuestos heterociclicos | |
IN2014CN02639A (de) | ||
IN2014MN02598A (de) | ||
CR20130539A (es) | Triazolopiridinas | |
UY33977A (es) | Híbrido de pigmento autoaglutinante. | |
BR112014003027A2 (pt) | formulação herbicida melhorada | |
UY34158A (es) | Composicion herbicida | |
CO7151478A2 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-dll4 | |
BR112014027219A2 (pt) | método | |
DK2858989T3 (da) | Amorf form af en AKT-hæmmende pyrimidinyl-cyclopentan-forbindelse, sammensætninger deraf og fremgangsmåder dertil | |
CO6801755A2 (es) | Formulaciones de otamixaban con estabilidad mejorada | |
AU2013347232A8 (en) | 3-Aminocyclopentane carboxamide derivatives | |
BR112014002498A2 (pt) | “composição de tratamento oral não aquosa” | |
IN2012DE02933A (de) |